I think the odds of antithrombin having extended utility are good also. I think the skepticism that is out there is much larger than market size of this one product. I believe the big money wants to see the size of this initial market, and evidence that the platform is providing the cost advantage that made it so attractive 10 years ago. The skepticism is not just about GTCB and its management, but rather transgenics as a whole.
Market Data 
Markets 
AI
